1. Chemical carcinogen safety testing: OECD expert group international consensus on the development of an integrated approach for the testing and assessment of chemical non-genotoxic carcinogens
- Author
-
Marco Corvaro, Paule Vasseur, Monica Vaccari, Annamaria Colacci, Federica Madia, Martin Paparella, Akiyoshi Nishikawa, Nathalie Delrue, Kumiko Ogawa, Norman Ertych, Raffaella Corvi, Miriam N. Jacobs, Kiyomi Ohmori, M. Cecilia Aguila, Mirjam Luijten, Daniel Desaulniers, Anoop Kumar Sharma, Abigail Jacobs, Centre for Radiation, Chemical and Environmental Hazards, Public Health England [London], ARPA Emilia-Romagna, Agenzia Regionale per la Protezione dell’Ambiente, European Commission - Joint Research Centre [Ispra] (JRC), U.S. Food and Drug Administration (FDA), Organisation de Coopération et de Développement Economiques (OCDE), German Federal Institute for Risk Assessment [Berlin] (BfR), National Institute for Public Health and the Environment [Bilthoven] (RIVM), Innsbruck Medical University [Austria] (IMU), Technical University of Denmark [Lyngby] (DTU), Laboratoire Interdisciplinaire des Environnements Continentaux (LIEC), Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire Terre et Environnement de Lorraine (OTELo), Institut national des sciences de l'Univers (INSU - CNRS)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)-Institut Ecologie et Environnement (INEE), and Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Cancer microenvironment ,0301 basic medicine ,Consensus ,Carcinogenicity Tests ,[SDV]Life Sciences [q-bio] ,Cancer hallmarks ,Health, Toxicology and Mutagenesis ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Context (language use) ,Toxicology ,medicine.disease_cause ,Risk Assessment ,Cancer prevention ,Meeting Reports ,03 medical and health sciences ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Adverse Outcome Pathway ,medicine ,Animals ,Humans ,Cancer model ,Integrated approaches to testing and assessment ,Carcinogen ,Non-genotoxic carcinogenicity ,Reproducibility of Results ,General Medicine ,Integrated approach ,Expert group ,3. Good health ,Variety (cybernetics) ,030104 developmental biology ,Risk analysis (engineering) ,030220 oncology & carcinogenesis ,Carcinogens ,Identification (biology) ,IATA ,Business ,Hazard assessment ,Genotoxicity - Abstract
While regulatory requirements for carcinogenicity testing of chemicals vary according to product sector and regulatory jurisdiction, the standard approach starts with a battery of genotoxicity tests (which include mutagenicity assays). If any of the in vivo genotoxicity tests are positive, a lifetime rodent cancer bioassay may be requested, but under most chemical regulations (except plant protection, biocides, pharmaceuticals), this is rare. The decision to conduct further testing based on genotoxicity test outcomes creates a regulatory gap for the identification of non-genotoxic carcinogens (NGTxC). With the objective of addressing this gap, in 2016, the Organization of Economic Cooperation and Development (OECD) established an expert group to develop an integrated approach to the testing and assessment (IATA) of NGTxC. Through that work, a definition of NGTxC in a regulatory context was agreed. Using the adverse outcome pathway (AOP) concept, various cancer models were developed, and overarching mechanisms and modes of action were identified. After further refining and structuring with respect to the common hallmarks of cancer and knowing that NGTxC act through a large variety of specific mechanisms, with cell proliferation commonly being a unifying element, it became evident that a panel of tests covering multiple biological traits will be needed to populate the IATA. Consequently, in addition to literature and database investigation, the OECD opened a call for relevant assays in 2018 to receive suggestions. Here, we report on the definition of NGTxC, on the development of the overarching NGTxC IATA, and on the development of ranking parameters to evaluate the assays. Ultimately the intent is to select the best scoring assays for integration in an NGTxC IATA to better identify carcinogens and reduce public health hazards. Electronic supplementary material The online version of this article (10.1007/s00204-020-02784-5) contains supplementary material, which is available to authorized users.
- Published
- 2020
- Full Text
- View/download PDF